Streetbeat News

Regulatory

KALV

KalVista Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for Sebetralstat, an oral plasma kallikrein inhibitor for treating hereditary angioedema (HAE) attacks. The FDA will review the NDA within 60 days, with a decision expected in September. KalVista plans to seek additional marketing authorizations globally in 2024.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 10:32 am

CALT

Calliditas Therapeutics has received a patent for NOX inhibitors, which are intended for the treatment of cancer. This development could potentially enhance their product portfolio and market position in the oncology sector.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 10:27 am

ASNS

AWIN

CHGG

MBIO

NLSP

QMCO

Chegg, Inc. (NYSE:CHGG) shares surged 20.7% in pre-market trading following the announcement of a restructuring plan, including a 23% headcount reduction and a focus on international programs. Other notable pre-market movers include Actelis Networks, Inc. (NASDAQ:ASNS) up 112.2%, NLS Pharmaceutics AG (NASDAQ:NLSP) up 62.8%, and Mustang Bio, Inc. (NASDAQ:MBIO) up 46.7%. On the losing side, AERWINS Technologies Inc. (NASDAQ:AWIN) fell 48.8% and Quantum Corporation (NASDAQ:QMCO) dropped 38%.

Portfolio Pulse from Avi Kapoor

June 18, 2024 | 9:28 am

TM

Toyota Chairman Akio Toyoda has been re-elected despite decreased shareholder support and governance issues. The reappointment was expected due to Toyota's shareholdings by other group firms and Toyoda's popularity among retail investors. However, a significant drop in shareholder support could prompt further governance reforms. Toyota has faced safety and certification testing violations, leading to a 10% drop in shares since the revelations, though shares are still up 18% for the year.

Portfolio Pulse from Benzinga Neuro

June 18, 2024 | 9:14 am

GWAV

Greenwave Technology Solutions has regained compliance with Nasdaq's listing requirements, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 8:34 am

RHHBY

Roche's VENTANA DP 200 Digital System has received FDA approval for diagnostic use, enabling pathologists to diagnose patients using digital images. This approval is a significant step in Roche's commitment to digital pathology solutions.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 6:03 am

BA

Boeing's CEO David Calhoun will testify before U.S. senators regarding the company's safety measures amid ongoing investigations by the NTSB and FAA. The hearing follows a 737 Max incident and ongoing scrutiny of Boeing's safety practices. Despite efforts to address these issues, Boeing continues to face challenges, including a recent FAA investigation into falsely documented titanium parts.

Portfolio Pulse from Benzinga Neuro

June 18, 2024 | 5:42 am

STZ

TAP

TLRY

A new study led by Dr. Erika Rosen highlights that cannabis is less harmful than alcohol and opioids, suggesting a shift in consumer preferences towards cannabis-infused beverages. This shift presents growth opportunities for the cannabis beverage market. Companies like Constellation Brands, Molson Coors, and Tilray are already investing in this space.

Portfolio Pulse from Nicolás Jose Rodriguez

June 18, 2024 | 4:51 am

EWA

The Reserve Bank of Australia has decided to keep the interest rate unchanged at 4.35% for June. This decision may impact various financial instruments, including the iShares MSCI Australia ETF (EWA).

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 4:30 am

VSME

Trading for VSME was halted at 7:50:00 p.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:50 pm